‹ ›
MYP_150492
← PREVIOUS NEXT → BACK
Basic Information
P6-4
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Standard
20 amino acids
C105H139N25O25S
Standard
Sequence
PNGPWVWVPAFCQAVGWGDP
Physicochemical Analysis
2183.44 Da
4.05
-1.05
-1.12
-0.0525
0.04
0.30
0.39
4.29
53.50
0.2000
16500.00
16500.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
746.71
-3.59
25.0
25.0
55.0
156.0
11.0
21.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0014623 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells
11.88 μM
IC50
PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0018571 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0042101 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 (RU570) | TZM-bl cells
8.04 μM
IC50
Mammalian: >20 h; Yeast: >20 h; E. coli: ?
PaperPeptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. | Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. | J Virol. 2011 Jul;85(14):7037-47. | DOI:10.1128/JVI.02366-10 | PMID:21543477 PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0317853 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 (92UG024) | TZM-bl cells
11.88 μM
IC50
Mammalian: >20 h; Yeast: >20 h; E. coli: ?
PaperPeptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. | Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. | J Virol. 2011 Jul;85(14):7037-47. | DOI:10.1128/JVI.02366-10 | PMID:21543477 PMID21543477 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21543477/
RECORD: Rec_0322429 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperHIPdb: a database of experimentally validated HIV inhibiting peptides PMID23359817 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23359817/
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2